Key baseline characteristics
| Characteristics . | N = 20 . |
|---|---|
| Age at diagnosis, y | |
| Median (range) | 65 (44-87) |
| Subgroup, n (%) | |
| 18 to <65 | 10 (50) |
| ≥65 to <75 | 7 (35) |
| ≥75 | 3 (15) |
| Male, n (%) | 9 (45) |
| Race/ancestry, n (%) | |
| White | 15 (75) |
| African American | 4 (20) |
| Missing | 1 (5) |
| Past medical history, n (%) | |
| Chronic kidney disease before diagnosis (GFR, 30-59 mL/min) | 3 (15) |
| Hypertension | 9 (45) |
| Diabetes | 4 (20) |
| Peak SCr at admission, median (range), mg/dL | 6.5 (3.1-17.8) |
| eGFR (CKD-EPI), median (range), mL/min per 1.73 m2 | 8 (2-16) |
| Requiring dialysis during hospitalization, n (%) | 9 (45) |
| Peak involved sFLC at diagnosis, median (range), mg/L | 6603 (1839-26 023) |
| MM subtype, n (%) | |
| κ light chain | 7 (35) |
| λ light chain | 6 (30) |
| IgG κ | 2 (10) |
| IgG λ | 3 (15) |
| IgA κ | 1 (5) |
| IgA λ | 1 (5) |
| R-ISS stage, n (%) | |
| Stage I | 0 (0) |
| Stage II | 6 (30) |
| Stage III | 14 (70) |
| High-risk cytogenetics by FISH, n (%) | |
| del17p | 1 (5) |
| t(4;14) | 3 (15) |
| t(14;16) | 1 (5) |
| HRCAs∗ , n (%) | |
| 0 | 9 (45) |
| 1 | 9 (45) |
| ≥2 | 2 (10) |
| Extramedullary disease, n (%) | 2 (10) |
| Characteristics . | N = 20 . |
|---|---|
| Age at diagnosis, y | |
| Median (range) | 65 (44-87) |
| Subgroup, n (%) | |
| 18 to <65 | 10 (50) |
| ≥65 to <75 | 7 (35) |
| ≥75 | 3 (15) |
| Male, n (%) | 9 (45) |
| Race/ancestry, n (%) | |
| White | 15 (75) |
| African American | 4 (20) |
| Missing | 1 (5) |
| Past medical history, n (%) | |
| Chronic kidney disease before diagnosis (GFR, 30-59 mL/min) | 3 (15) |
| Hypertension | 9 (45) |
| Diabetes | 4 (20) |
| Peak SCr at admission, median (range), mg/dL | 6.5 (3.1-17.8) |
| eGFR (CKD-EPI), median (range), mL/min per 1.73 m2 | 8 (2-16) |
| Requiring dialysis during hospitalization, n (%) | 9 (45) |
| Peak involved sFLC at diagnosis, median (range), mg/L | 6603 (1839-26 023) |
| MM subtype, n (%) | |
| κ light chain | 7 (35) |
| λ light chain | 6 (30) |
| IgG κ | 2 (10) |
| IgG λ | 3 (15) |
| IgA κ | 1 (5) |
| IgA λ | 1 (5) |
| R-ISS stage, n (%) | |
| Stage I | 0 (0) |
| Stage II | 6 (30) |
| Stage III | 14 (70) |
| High-risk cytogenetics by FISH, n (%) | |
| del17p | 1 (5) |
| t(4;14) | 3 (15) |
| t(14;16) | 1 (5) |
| HRCAs∗ , n (%) | |
| 0 | 9 (45) |
| 1 | 9 (45) |
| ≥2 | 2 (10) |
| Extramedullary disease, n (%) | 2 (10) |
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; FISH, fluorescence in situ hybridization; HRCAs, high-risk cytogenetic abnormalities; IgG, immunoglobulin G; R-ISS, revised International Staging System; SCr, serum creatinine.
HRCAs include any of del(17p), t(4;14), t(14;16), t(14;20), or 1q21 gain/amplification.